The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Amgen Calls Off Clinical Studies of Rilotumumab for Gastric Cancer
November 26, 2014
- MSD to Ensure Appropriate Use of Insomnia Drug Belsomra
November 26, 2014
- Eisai Launches Halaven in Brazil
November 26, 2014
- Eisai Launches Fycompa in Hong Kong
November 26, 2014
- MSD Seeks Japan Regulatory Approval for Once-Weekly DPP-4 Inhibitor
November 25, 2014
- Rushed Settlements Dragged Down Drug Delivery Prices: Vital KSK Exec
November 25, 2014
- Merck Serono Transfers Marketing Rights for Saizen to Fujifilm Pharma
November 25, 2014
- Top Two Japan Universities to Offer Undergrads Amgen-Sponsored Lab Experience Programs
November 21, 2014
- Domestic Subgroup Analysis Confirms Efficacy of Cimzia: Astellas, UCB Japan
November 21, 2014
- Kissei Files NDA for Hyperphosphatemia Treatment in Japan
November 21, 2014
- CareNet Teams Up with Indian Firm on Marketing Solutions for Drug Makers
November 20, 2014
- Ranbaxy Sues FDA for Revoking Tentative Approvals for Nexium, Valcyte Generics
November 20, 2014
- Takeda Ordered to Pay US$155,000 for Spoliation of Evidence in Actos Case
November 20, 2014
- Nipro Pharma Joins Hands with Thai Firm on Drug Distribution
November 20, 2014
- Mirena Approved for Dysmenorrhea Based on Data from Public Domain: Bayer Yakuhin
November 20, 2014
- 30% of Pharmacies Handling Blopress AGs Likely to Use Other Makers’ Generics: Survey
November 19, 2014
- Topical Combination Agent for Plaque Psoriasis Showed Superiority to Monotherapies in PIII Trial: Maruho
November 19, 2014
- Giotrif Extends Overall Survival in Japanese NSCLC Patients with Del19 EGFR Mutation: NBI
November 19, 2014
- Valtrex Adult Indications Approved for Children: GSK
November 19, 2014
- Inderal Tablets Approved for Prevention of Hypoxic Episodes: AZ
November 19, 2014
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…